Belantamab Mafodotin Plus Vd More Than Doubles PFS in Relapsed/Refractory Multiple Myeloma

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma.

Related Keywords

United States ,Roche Genentech ,Rachid Baz ,Abbvie Genentech ,International Staging System ,Amgen ,Moffitt Cancer Center ,Glaxosmithkline ,Pfizer ,Revised International Staging System ,Belantamab Mafodotin ,Multiple Myeloma ,Abvd ,Dvd ,Phase 3 Dreamm 7 Trial ,2024 February Asco Plenary Series ,Maria Victoria Mateos ,Phd ,Hospital Universitario De Salamanca ,